Which has higher valuation and earnings, INCY or ABBV?

AbbVie has higher revenue and earnings than Incyte. AbbVie is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.82 $1.29B $1.88 64.73 AbbVie $61.16B 8.52 $4.23B $5.81 50.73

Is INCY or ABBV more profitable?

AbbVie has a net margin of 15.67% compared to Incyte's net margin of 6.71%. Incyte's return on equity of 7.92% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 6.71% 7.92% 6.12% AbbVie 15.67% -450.55% 16.50%

Does the media favor INCY or ABBV?

In the previous week, AbbVie had 29 more articles in the media than Incyte. MarketBeat recorded 48 mentions for AbbVie and 19 mentions for Incyte. AbbVie's average media sentiment score of 1.14 beat Incyte's score of 0.50 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive AbbVie 37 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, MRNA or INCY?

Incyte has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 48.15 -$2.82B -$7.10 N/A Incyte $5.14B 4.82 $1.29B $1.88 64.73

Is MRNA or INCY more profitable?

Incyte has a net margin of 6.71% compared to Moderna's net margin of -110.46%. Incyte's return on equity of 7.92% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -110.46% -25.79% -15.85% Incyte 6.71% 7.92% 6.12%

Does the media prefer MRNA or INCY?

In the previous week, Moderna had 60 more articles in the media than Incyte. MarketBeat recorded 79 mentions for Moderna and 19 mentions for Incyte. Moderna's average media sentiment score of 0.58 beat Incyte's score of 0.50 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 29 Very Positive mention(s) 15 Positive mention(s) 16 Neutral mention(s) 4 Negative mention(s) 5 Very Negative mention(s) Positive Incyte 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media prefer REGN or INCY?

In the previous week, Regeneron Pharmaceuticals had 9 more articles in the media than Incyte. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 19 mentions for Incyte. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Incyte's score of 0.50 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 9 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has higher valuation and earnings, INCY or NTRA?

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.82 $1.29B $1.88 64.73 Natera $2.31B 20.31 -$208.16M -$1.14 N/A

Is INCY or NTRA more profitable?

Incyte has a net margin of 6.71% compared to Natera's net margin of -5.66%. Incyte's return on equity of 7.92% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 6.71% 7.92% 6.12% Natera -5.66% -8.61% -5.93%

Does the media refer more to INCY or NTRA?

In the previous week, Natera had 6 more articles in the media than Incyte. MarketBeat recorded 25 mentions for Natera and 19 mentions for Incyte. Incyte's average media sentiment score of 0.50 beat Natera's score of 0.16 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive Natera 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ARGX or INCY?

argenex has higher earnings, but lower revenue than Incyte. argenex is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 14.53 $1.29B $28.66 34.24 Incyte $5.14B 4.82 $1.29B $1.88 64.73

Is ARGX or INCY more profitable?

argenex has a net margin of 31.66% compared to Incyte's net margin of 6.71%. argenex's return on equity of 47.70% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.66% 47.70% 40.12% Incyte 6.71% 7.92% 6.12%

Does the media refer more to ARGX or INCY?

In the previous week, argenex had 2 more articles in the media than Incyte. MarketBeat recorded 21 mentions for argenex and 19 mentions for Incyte. argenex's average media sentiment score of 0.63 beat Incyte's score of 0.50 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 8 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Incyte (INCY) Competitors

$120.34 -1.36 (-1.12%)

As of 12:28 PM Eastern

Compare

INCY vs. ABBV, MRNA, REGN, NTRA, and ARGX

Should you buy Incyte stock or one of its competitors? Incyte's main competitors and comparable companies include AbbVie (ABBV), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Natera (NTRA), and argenex (ARGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Incyte compare to AbbVie?

Incyte (NASDAQ:INCY) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

AbbVie has higher revenue and earnings than Incyte. AbbVie is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.82	$1.29B	$1.88	64.73
AbbVie	$61.16B	8.52	$4.23B	$5.81	50.73

Incyte has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Incyte presently has a consensus price target of $132.86, indicating a potential upside of 9.17%. AbbVie has a consensus price target of $297.46, indicating a potential upside of 0.92%. Given Incyte's higher possible upside, research analysts clearly believe Incyte is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40
AbbVie	0 Sell rating(s)	6 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, AbbVie had 29 more articles in the media than Incyte. MarketBeat recorded 48 mentions for AbbVie and 19 mentions for Incyte. AbbVie's average media sentiment score of 1.14 beat Incyte's score of 0.50 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
AbbVie	37 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AbbVie has a net margin of 15.67% compared to Incyte's net margin of 6.71%. Incyte's return on equity of 7.92% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	6.71%	7.92%	6.12%
AbbVie	15.67%	-450.55%	16.50%

97.0% of Incyte shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbbVie beats Incyte on 11 of the 17 factors compared between the two stocks.

How does Incyte compare to Moderna?

Moderna (NASDAQ:MRNA) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Incyte has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	48.15	-$2.82B	-$7.10	N/A
Incyte	$5.14B	4.82	$1.29B	$1.88	64.73

75.3% of Moderna shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Incyte has a net margin of 6.71% compared to Moderna's net margin of -110.46%. Incyte's return on equity of 7.92% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-110.46%	-25.79%	-15.85%
Incyte	6.71%	7.92%	6.12%

Moderna presently has a consensus target price of $113.75, suggesting a potential downside of 50.83%. Incyte has a consensus target price of $132.86, suggesting a potential upside of 9.17%. Given Incyte's stronger consensus rating and higher possible upside, analysts clearly believe Incyte is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	15 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.08
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40

Moderna has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Incyte has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

In the previous week, Moderna had 60 more articles in the media than Incyte. MarketBeat recorded 79 mentions for Moderna and 19 mentions for Incyte. Moderna's average media sentiment score of 0.58 beat Incyte's score of 0.50 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	29 Very Positive mention(s)	15 Positive mention(s)	16 Neutral mention(s)	4 Negative mention(s)	5 Very Negative mention(s)	Positive
Incyte	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Incyte beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Incyte compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

Regeneron Pharmaceuticals has a beta of 0.1, indicating that its stock price is 90% less volatile than the broader market. Comparatively, Incyte has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	6.86	$4.50B	$45.29	21.00
Incyte	$5.14B	4.82	$1.29B	$1.88	64.73

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Regeneron Pharmaceuticals had 9 more articles in the media than Incyte. MarketBeat recorded 28 mentions for Regeneron Pharmaceuticals and 19 mentions for Incyte. Regeneron Pharmaceuticals' average media sentiment score of 0.72 beat Incyte's score of 0.50 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	9 Very Positive mention(s)	6 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals currently has a consensus price target of $898.97, suggesting a potential downside of 5.49%. Incyte has a consensus price target of $132.86, suggesting a potential upside of 9.17%. Given Incyte's higher probable upside, analysts clearly believe Incyte is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40

Regeneron Pharmaceuticals has a net margin of 28.51% compared to Incyte's net margin of 6.71%. Regeneron Pharmaceuticals' return on equity of 16.01% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	28.51%	16.01%	12.22%
Incyte	6.71%	7.92%	6.12%

Summary

Regeneron Pharmaceuticals beats Incyte on 12 of the 17 factors compared between the two stocks.

How does Incyte compare to Natera?

Incyte (NASDAQ:INCY) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Incyte currently has a consensus target price of $132.86, indicating a potential upside of 9.17%. Natera has a consensus target price of $394.31, indicating a potential upside of 22.10%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40
Natera	2 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.83

Incyte has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Natera has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

97.0% of Incyte shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Natera had 6 more articles in the media than Incyte. MarketBeat recorded 25 mentions for Natera and 19 mentions for Incyte. Incyte's average media sentiment score of 0.50 beat Natera's score of 0.16 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Natera	5 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral

Incyte has a net margin of 6.71% compared to Natera's net margin of -5.66%. Incyte's return on equity of 7.92% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	6.71%	7.92%	6.12%
Natera	-5.66%	-8.61%	-5.93%

Incyte has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.82	$1.29B	$1.88	64.73
Natera	$2.31B	20.31	-$208.16M	-$1.14	N/A

Summary

Incyte beats Natera on 9 of the 17 factors compared between the two stocks.

How does Incyte compare to argenex?

argenex (NASDAQ:ARGX) and Incyte (NASDAQ:INCY) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

argenex has a net margin of 31.66% compared to Incyte's net margin of 6.71%. argenex's return on equity of 47.70% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.66%	47.70%	40.12%
Incyte	6.71%	7.92%	6.12%

argenex has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Incyte has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

argenex presently has a consensus price target of $1,158.76, indicating a potential upside of 18.08%. Incyte has a consensus price target of $132.86, indicating a potential upside of 9.17%. Given argenex's stronger consensus rating and higher possible upside, equities research analysts plainly believe argenex is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	6 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.82
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40

argenex has higher earnings, but lower revenue than Incyte. argenex is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	14.53	$1.29B	$28.66	34.24
Incyte	$5.14B	4.82	$1.29B	$1.88	64.73

In the previous week, argenex had 2 more articles in the media than Incyte. MarketBeat recorded 21 mentions for argenex and 19 mentions for Incyte. argenex's average media sentiment score of 0.63 beat Incyte's score of 0.50 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	8 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

60.3% of argenex shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

argenex beats Incyte on 12 of the 17 factors compared between the two stocks.

Get Incyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCY vs. The Competition

Export

Metric	Incyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.52B	$4.08B	$7.83B	$12.01B
Dividend Yield	N/A	3.62%	2.46%	4.50%
P/E Ratio	63.99	24.52	34.41	30.36
Price / Sales	4.77	16.83	8.86	5.82
Price / Cash	19.78	26.89	22.23	22.80
Price / Book	4.35	4.13	4.39	3.77
Net Income	$1.29B	-$22.78M	$3.51B	$390.55M
7 Day Performance	0.58%	-2.84%	-1.68%	-0.58%
1 Month Performance	10.79%	-5.81%	-4.09%	-6.84%
1 Year Performance	14.17%	-0.42%	0.66%	-6.12%

Incyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCY Incyte	2.9595 of 5 stars	$120.34 -1.1%	$132.86 +10.4%	+12.4%	$24.52B	$5.14B	63.99	2,844	Insider Trade
ABBV AbbVie	3.7877 of 5 stars	$288.66 -2.1%	$294.67 +2.1%	+26.3%	$505.29B	$61.16B	26.31	57,000	Trending News Insider Trade
MRNA Moderna	1.6966 of 5 stars	$220.83 -0.4%	$107.10 -51.5%	+766.2%	$85.50B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Revision Gap Down
REGN Regeneron Pharmaceuticals	3.9041 of 5 stars	$961.26 +3.6%	$898.97 -6.5%	+39.5%	$83.73B	$14.34B	20.87	15,410	High Trading Volume
NTRA Natera	3.3434 of 5 stars	$378.92 -8.5%	$394.31 +4.1%	+54.1%	$61.18B	$2.31B	N/A	6,140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCY) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Incyte (INCY) Competitors